Communications Biology (Apr 2021)
Structure and function analysis of a potent human neutralizing antibody CA521FALA against SARS-CoV-2
- Deyong Song,
- Wenbo Wang,
- Chuangchuang Dong,
- Zhenfei Ning,
- Xiu Liu,
- Chuan Liu,
- Guangying Du,
- Chunjie Sha,
- Kailin Wang,
- Jun Lu,
- Baiping Sun,
- Yanyan Zhao,
- Qiaoping Wang,
- Hongguang Xu,
- Ying Li,
- Zhenduo Shen,
- Jie Jiao,
- Ruiying Wang,
- Jingwei Tian,
- Wanhui Liu,
- Lan Wang,
- Yong-Qiang Deng,
- Changlin Dou
Affiliations
- Deyong Song
- Antibody Research and Development Center, Shandong Boan Biotechnology Co., Ltd.
- Wenbo Wang
- Division of Monoclonal Antibodies, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC)
- Chuangchuang Dong
- Antibody Research and Development Center, Shandong Boan Biotechnology Co., Ltd.
- Zhenfei Ning
- Antibody Research and Development Center, Shandong Boan Biotechnology Co., Ltd.
- Xiu Liu
- Antibody Research and Development Center, Shandong Boan Biotechnology Co., Ltd.
- Chuan Liu
- Shuimu BioSciences Ltd.
- Guangying Du
- State Key Laboratory of Long-acting and Targeting Drug Delivery System, Shandong Luye Pharmaceutical Co. Ltd.
- Chunjie Sha
- State Key Laboratory of Long-acting and Targeting Drug Delivery System, Shandong Luye Pharmaceutical Co. Ltd.
- Kailin Wang
- Antibody Research and Development Center, Shandong Boan Biotechnology Co., Ltd.
- Jun Lu
- Antibody Research and Development Center, Shandong Boan Biotechnology Co., Ltd.
- Baiping Sun
- Antibody Research and Development Center, Shandong Boan Biotechnology Co., Ltd.
- Yanyan Zhao
- Antibody Research and Development Center, Shandong Boan Biotechnology Co., Ltd.
- Qiaoping Wang
- Antibody Research and Development Center, Shandong Boan Biotechnology Co., Ltd.
- Hongguang Xu
- Antibody Research and Development Center, Shandong Boan Biotechnology Co., Ltd.
- Ying Li
- Antibody Research and Development Center, Shandong Boan Biotechnology Co., Ltd.
- Zhenduo Shen
- Antibody Research and Development Center, Shandong Boan Biotechnology Co., Ltd.
- Jie Jiao
- Antibody Research and Development Center, Shandong Boan Biotechnology Co., Ltd.
- Ruiying Wang
- State Key Laboratory of Long-acting and Targeting Drug Delivery System, Shandong Luye Pharmaceutical Co. Ltd.
- Jingwei Tian
- State Key Laboratory of Long-acting and Targeting Drug Delivery System, Shandong Luye Pharmaceutical Co. Ltd.
- Wanhui Liu
- State Key Laboratory of Long-acting and Targeting Drug Delivery System, Shandong Luye Pharmaceutical Co. Ltd.
- Lan Wang
- Division of Monoclonal Antibodies, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC)
- Yong-Qiang Deng
- State Key Laboratory of Pathogen and Biosecurity, Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences
- Changlin Dou
- Antibody Research and Development Center, Shandong Boan Biotechnology Co., Ltd.
- DOI
- https://doi.org/10.1038/s42003-021-02029-w
- Journal volume & issue
-
Vol. 4,
no. 1
pp. 1 – 11
Abstract
Song et al describe and identify monoclonal antibodies that target the SARSCoV-2 Spike protein, including CA521FALA, which demonstrated neutralising potential in vivo and in vitro. They performed structural analysis, which revealed that CA521FALA recognizes an epitope overlapping with angiotensin converting enzyme 2 (ACE2)-binding sites in SARS-CoV-2 Spike protein therefore making it a promising therapeutic antibody.
